Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial

08:03 AM EDT, 09/25/2026 (MT Newswires) -- Fate Therapeutics (FATE) has been awarded a $15 million grant from the California Institute for Regenerative Medicine to support its clinical development of a phase 2 trial for FT819, a potential treatment for patients with moderate-to-severe systemic lupus erythematosus with lupus nephritis, the company said Friday. Lupus nephritis is a deadly condition that develops in patients with lupus, a severe autoimmune condition. Shares of the company rose more than 4% in recent premarket activity Friday. Price: 2.44, Change: +0.11, Percent Change: +4.72